Evidence map›Paper›PMID 38868308›Full record

ReviewOpen forum infectious diseases2024

Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens.

Thomas P Lodise, Keith S Kaye, Anne Santerre Henriksen, Gunnar Kahlmeter

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07407673 (Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07407673 phase3not yet recruitingnot on this mapstarted 2027, after this paper: background citation

Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study

TypeinterventionalSponsorSusanne Dam Nielsen, MD, DMScRan2027 to 2041Enrolled180ConditionsKidney Transplant Infection, Bloodstream Infection, Kidney Transplant, Kidney Transplant RecipientsArmsPivmecillinam, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. The mecillinam resistome inAntimicrobial agents and chemotherapy · 2026
    Article
  3. MappingAntibiotics (Basel, Switzerland) · 2026
    Article
  4. Pivmecillinam for Treatment of Uncomplicated Urinary Tract Infection: New Efficacy Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  5. New Perspectives on Antimicrobial Agents: Pivmecillinam.Antimicrobial agents and chemotherapy · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thomas P LodiseDepartment of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.ORCID https://orcid.org/0000-0002-4730-0655
Keith S KayeDepartment of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.ORCID https://orcid.org/0000-0003-2051-1732
Anne Santerre HenriksenMaxel Consulting ApS, Jyllinge, Denmark.
Gunnar KahlmeterDepartment of Clinical Microbiology, Central Hospital, Växjö, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-line agent for the treatment of uncomplicated UTIs (uUTIs) and is now approved in the United States. We performed a structured literature search to review the available evidence on susceptibility of common uUTI-causing uropathogens to mecillinam. Among 38 studies included in this literature review, susceptibility rates for

Indexed as

EnterobacteralesESBLmecillinamresistanceuncomplicated urinary tract infection

Identifiers

PMID38868308
PMCPMC11167674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.